|
|
|
Volumn 118, Issue 1225, 2005, Pages
|
|
PHARMAC's response on gemcitabine and transparency.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC ANTIMETABOLITE;
DEOXYCYTIDINE;
DRUG DERIVATIVE;
GEMCITABINE;
BLADDER TUMOR;
DRUG APPROVAL;
ECONOMICS;
HUMAN;
METHODOLOGY;
NEW ZEALAND;
NOTE;
ORGANIZATION AND MANAGEMENT;
PUBLIC HEALTH;
TRANSITIONAL CELL CARCINOMA;
ANTIMETABOLITES, ANTINEOPLASTIC;
CARCINOMA, TRANSITIONAL CELL;
DEOXYCYTIDINE;
DRUG APPROVAL;
HUMANS;
NATIONAL HEALTH PROGRAMS;
NEW ZEALAND;
URINARY BLADDER NEOPLASMS;
|
|
EID: 33644820911
PISSN: None
EISSN: 11758716
Source Type: Journal
DOI: None Document Type: Note |
|
Times cited : (1)
|
|
References (0)
|
